RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer August 12, 2024 - Oncology, rare diseases, and immunology will likely continue to be hot targets for investors, and snapping up drugs from smaller startups has advantages over in-house development.
“What we’re seeing is the elimination of riskier and longer-shot products in the R&D portfolio for the big pharma companies, basically swapping those out for acquisitions with more potential than the products they’re cutting,” according to Michael Abrams , Managing Partner, Numerof & Associates.
And in terms of cash to make these deals, Big Pharma has it. Many companies are sitting on substantial war chests from the successful products that they’ve had over the last decade, Abrams said. In 2023, companies had about $1.37 trillion available to deploy.
“It’s going to be a very active M&A story over the balance of the year and into next year,” Abrams said.